Autolus Therapeutics (AUTL) Earnings Analysis

Autolus Therapeutics (AUTL) next reports earnings on 2026-08-11, consensus EPS -0.22 USD. Last quarter (2026-05-14) it beat with EPS -0.27 USD vs -0.29 USD est (+6.9%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -1.32.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AUTL next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.22 USD
Revenue estimate0.03B

AUTL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.27 USD-0.29 USD+6.9%Beat
2026-03-27-0.34 USD-0.25993 USD-30.8%Miss
2025-05-08-0.26 USD-0.24 USD-8.3%Miss
2025-03-20-0.09 USD-0.21 USD+57.1%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

AUTL valuation and analyst view

Trailing P/E-1.32
Trailing EPS-1.08526 USD
Price / book3.52
Dividend yield0.00%
Market cap0.38B
Analyst consensusBuy (11 buy / 3 hold / 0 sell)

Related research pages

Frequently asked questions

When is Autolus Therapeutics (AUTL)'s next earnings date?

Autolus Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.22 USD and revenue estimate of 0.03B.

Did AUTL beat earnings last quarter?

In its 2026-05-14 report, AUTL posted EPS of -0.27 USD versus a -0.29 USD estimate — a beat of 6.9%.

What is AUTL's earnings track record?

Over the last 4 reported quarters with consensus data, AUTL beat estimates 2 times (50%).

What is AUTL's current P/E ratio and EPS?

AUTL trades at a trailing P/E of -1.32 on trailing EPS of -1.08525878856485 USD.

What do analysts rate AUTL?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell).